37 research outputs found
Interleukin-6 inhibitors: from the therapy of immuno-inflammatory rheumatic diseases to use in COVID-19
The key role inΒ the development ofΒ chronic autoimmune inflammation is played by pro-inflammatory cytokines, inΒ particular, interleukin 6Β (IL-6). The introduction into clinical practice ofΒ monoclonal antibodies inhibiting IL-6Β is aΒ significant event inΒ rheumatology and is currently considered as aΒ promising direction inΒ the treatment ofΒ immuno-inflammatory rheumatic diseases. The first inhibitor ofΒ IL-6Β (IL-6), which entered theΒ practice ofΒ rheumatologists, was tocilizumab (TCZ), theΒ secondΒ β sarilumab (SAR). Numerous studies have shown theΒ high effectiveness ofΒ iIL-6: theΒ use ofΒ drugs leads to aΒ rapid decrease inΒ the clinical manifestations ofΒ rheumatoid arthritis (RA) and aΒ decrease inΒ laboratory signs ofΒ inflammation, contributing to theΒ achievement ofΒ low activity or remission, improves theΒ quality ofΒ life ofΒ patients, and also slows down theΒ X-ray progression ofΒ the disease. At theΒ same time, iIL-6Β has aΒ satisfactory safety profile. The universal problem ofΒ our timeΒ β theΒ pandemic ofΒ a new coronavirus infectionΒ β has led to attempts to use IL-6Β in patients with severe and critical disease, since IL-6Β plays an important role inΒ the pathogenesis ofΒ COVID-19, which is confirmed by theΒ results ofΒ numerous studies. However, data on theΒ efficacy and safety ofΒ these drugs inΒ COVID-19 are contradictory, which requires conducting larger-scale controlled studies. This review examines theΒ issues ofΒ the effectiveness and safety ofΒ TCZ and SAR inΒ rheumatological patients and inΒ patients with COVID-19. The review is illustrated with examples from real clinical practice
Methods of probe microscopy in the study of topography and elastic properties of cold-resistant elastomers
The work was carried out under the financial support of the Russian Science Fund, grant 14-29-00198-Π(sample preparation and scanning electron microscopy) and the Federal Agency of Scientific Organizations - Agreement No 007-ΠΠ/Π§3363/26 (scanning probe microscopy)
ΠΠ΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ Π²Π°ΠΊΡΠΈΠ½ ΠΏΡΠΎΡΠΈΠ² COVID-19 Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΠΈΠΌΠΌΡΠ½ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠΌΠΈ ΡΠ΅Π²ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ (ΠΏΡΠ΅Π΄Π²Π°ΡΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅)
Objective: to assess the safety of COVID-19 vaccines in patients with immunoinflammatory rheumatic diseases (IRD) in real clinical practice.Patients and methods. A cross-sectional study of patients with IRD, who were admitted to V.A. Nasonova Research Institute of Rheumatology for inpatient or outpatient treatment. All patients received at least 1 dose of vaccine against COVID-19 (main group). The control group consisted of vaccinated persons without IRD. All participants were interviewed by the researcher by filling out a unified questionnaire, additional information was obtained from medical records.Results and discussion. The study included 204 patients with IRD (151 of them were vaccinated with Sputnik V, 31 with Sputnik Light, 19 with Π‘oviVac, 3 with EpiVacCorona; 173 patients received the second component of vaccine) and 131 subjects without IRD (101 of them were vaccinated with Sputnik V, 17 β CoviVak, 5 β Sputnik Light, 2 β EpiVacCorona, 6 β Pfizer/BioNTech; 124 patients received the second component of the vaccine). The number of patients with IRD who had both local and systemic reactions after administration of the first component of the vaccine was significantly less than in the control group (19.6 and 38.9%, respectively; p<0.001). Similar differences were noted after the administration of the second component (15.6 and 27.4%, respectively; p=0.013). Adverse events (AEs) such as pain at the injection site without restriction of movement, weakness, fever, arthralgia/myalgia and chills were significantly more common in the control group after the administration of the first component of the vaccine. After complete immunization, AEs were absent in 35.8% of patients with IRD and in 21% of controls (p=0.006). Exacerbations of IRD and new autoimmune phenomena were not registered in any case.Conclusion. According to preliminary data, vaccination against COVID-19 in patients with IRD appears to be quite safe. Further studies are needed to investigate the safety, immunogenicity, and clinical efficacy of COVID-19 immunization in rheumatic patients.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΎΡΠ΅Π½ΠΊΠ° Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ Π²Π°ΠΊΡΠΈΠ½ ΠΏΡΠΎΡΠΈΠ² COVID-19 Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΈΠΌΠΌΡΠ½ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠΌΠΈ ΡΠ΅Π²ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ (ΠΠΠ Π) Π² ΡΠ΅Π°Π»ΡΠ½ΠΎΠΉ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠ΅.ΠΠ°ΡΠΈΠ΅Π½ΡΡ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΠΎΠ΄Π½ΠΎΠΌΠΎΠΌΠ΅Π½ΡΠ½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠΎΡΡΡΠΏΠΈΠ²ΡΠΈΡ
Π½Π° ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ½ΠΎΠ΅ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΠΈΠ»ΠΈ ΠΎΠ±ΡΠ°ΡΠΈΠ²ΡΠΈΡ
ΡΡ Π² ΠΊΠΎΠ½ΡΡΠ»ΡΡΠ°ΡΠΈΠ²Π½ΠΎ-Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΠ΅Π½ΡΡ Π€ΠΠΠΠ£ Β«ΠΠ°ΡΡΠ½ΠΎ-ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΡΡΠΊΠΈΠΉ ΠΈΠ½ΡΡΠΈΡΡΡ ΡΠ΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈΠΌ. Π.Π. ΠΠ°ΡΠΎΠ½ΠΎΠ²ΠΎΠΉΒ» Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΠΠ Π, ΠΏΠΎΠ»ΡΡΠΈΠ²ΡΠΈΡ
ΠΊΠ°ΠΊ ΠΌΠΈΠ½ΠΈΠΌΡΠΌ 1 Π΄ΠΎΠ·Ρ Π²Π°ΠΊΡΠΈΠ½Ρ ΠΏΡΠΎΡΠΈΠ² COVID-19 (ΠΎΡΠ½ΠΎΠ²Π½Π°Ρ Π³ΡΡΠΏΠΏΠ°). ΠΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΡ Π³ΡΡΠΏΠΏΡ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ Π²Π°ΠΊΡΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ Π»ΠΈΡΠ° Π±Π΅Π· ΠΠΠ Π. ΠΡΠ΅ ΡΡΠ°ΡΡΠ½ΠΈΠΊΠΈ Π±ΡΠ»ΠΈ ΠΎΠΏΡΠΎΡΠ΅Π½Ρ Π²ΡΠ°ΡΠΎΠΌ-ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»Π΅ΠΌ Ρ Π·Π°ΠΏΠΎΠ»Π½Π΅Π½ΠΈΠ΅ΠΌ ΡΠ½ΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ Π°Π½ΠΊΠ΅ΡΡ, Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΡΡ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡ ΠΏΠΎΠ»ΡΡΠ°Π»ΠΈ ΠΈΠ· ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΉ Π΄ΠΎΠΊΡΠΌΠ΅Π½ΡΠ°ΡΠΈΠΈ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈ ΠΎΠ±ΡΡΠΆΠ΄Π΅Π½ΠΈΠ΅. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΎ 204 Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΠΠ Π (151 ΠΈΠ· Π½ΠΈΡ
Π±ΡΠ» Π²Π°ΠΊΡΠΈΠ½ΠΈΡΠΎΠ²Π°Π½ Π‘ΠΏΡΡΠ½ΠΈΠΊΠΎΠΌ V, 31 β Π‘ΠΏΡΡΠ½ΠΈΠΊΠΎΠΌ ΠΠ°ΠΉΡ, 19 β ΠΠΎΠ²ΠΈΠΠ°ΠΊΠΎΠΌ, 3 β ΠΠΏΠΈΠΠ°ΠΊΠΠΎΡΠΎΠ½ΠΎΠΉ; Π²ΡΠΎΡΠΎΠΉ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½Ρ Π²Π°ΠΊΡΠΈΠ½Ρ ΠΏΠΎΠ»ΡΡΠΈΠ»ΠΈ 173 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°) ΠΈ 131 ΠΈΡΠΏΡΡΡΠ΅ΠΌΡΠΉ Π±Π΅Π· ΠΠΠ Π (101 ΠΈΠ· Π½ΠΈΡ
Π±ΡΠ» Π²Π²Π΅Π΄Π΅Π½ Π‘ΠΏΡΡΠ½ΠΈΠΊ V, 17 β ΠΠΎΠ²ΠΈΠΠ°ΠΊ, 5 β Π‘ΠΏΡΡΠ½ΠΈΠΊ ΠΠ°ΠΉΡ, 2 β ΠΠΏΠΈΠΠ°ΠΊΠΠΎΡΠΎΠ½Π°, 6 β Pfizer/BioNTech; Π²ΡΠΎΡΠΎΠΉ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½Ρ Π²Π°ΠΊΡΠΈΠ½Ρ ΠΏΠΎΠ»ΡΡΠΈΠ»ΠΈ 124 ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π½ΡΡ
). ΠΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΠΠ Π, Ρ ΠΊΠΎΡΠΎΡΡΡ
Π±ΡΠ»ΠΈ Π·Π°ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π½Ρ ΠΊΠ°ΠΊ ΠΌΠ΅ΡΡΠ½ΡΠ΅, ΡΠ°ΠΊ ΠΈ ΡΠΈΡΡΠ΅ΠΌΠ½ΡΠ΅ ΡΠ΅Π°ΠΊΡΠΈΠΈ Π½Π° Π²Π²Π΅Π΄Π΅Π½ΠΈΠ΅ ΠΏΠ΅ΡΠ²ΠΎΠ³ΠΎ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠ° Π²Π°ΠΊΡΠΈΠ½Ρ, Π±ΡΠ»ΠΎ Π·Π½Π°ΡΠΈΠΌΠΎ ΠΌΠ΅Π½ΡΡΠ΅, ΡΠ΅ΠΌ Π² ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΠ΅ (19,6 ΠΈ 38,9% ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ; p<0,001). ΠΠ½Π°Π»ΠΎΠ³ΠΈΡΠ½ΡΠ΅ ΡΠ°Π·Π»ΠΈΡΠΈΡ ΠΎΡΠΌΠ΅ΡΠ°Π»ΠΈΡΡ ΠΈ ΠΏΠΎΡΠ»Π΅ Π²Π²Π΅Π΄Π΅Π½ΠΈΡ Π²ΡΠΎΡΠΎΠ³ΠΎ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠ° (15,6 ΠΈ 27,4% ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ; p=0,013). Π’Π°ΠΊΠΈΠ΅ Π½Π΅ΠΆΠ΅Π»Π°ΡΠ΅Π»ΡΠ½ΡΠ΅ ΡΠ²Π»Π΅Π½ΠΈΡ (ΠΠ―), ΠΊΠ°ΠΊ Π±ΠΎΠ»Ρ Π² ΠΌΠ΅ΡΡΠ΅ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Π±Π΅Π· ΠΎΠ³ΡΠ°Π½ΠΈΡΠ΅Π½ΠΈΡ Π΄Π²ΠΈΠΆΠ΅Π½ΠΈΡ, ΡΠ»Π°Π±ΠΎΡΡΡ, ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΡΠ΅ΠΌΠΏΠ΅ΡΠ°ΡΡΡΡ ΡΠ΅Π»Π°, Π°ΡΡΡΠ°Π»Π³ΠΈΠΈ/ΠΌΠΈΠ°Π»Π³ΠΈΠΈ ΠΈ ΠΎΠ·Π½ΠΎΠ± Π·Π½Π°ΡΠΈΠΌΠΎ ΡΠ°ΡΠ΅ Π²ΡΡΡΠ΅ΡΠ°Π»ΠΈΡΡ Π² ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΠ΅ ΠΏΠΎΡΠ»Π΅ Π²Π²Π΅Π΄Π΅Π½ΠΈΡ ΠΏΠ΅ΡΠ²ΠΎΠ³ΠΎ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠ° Π²Π°ΠΊΡΠΈΠ½Ρ. ΠΠΎΡΠ»Π΅ ΠΏΠΎΠ»Π½ΠΎΠΉ ΠΈΠΌΠΌΡΠ½ΠΈΠ·Π°ΡΠΈΠΈ ΠΠ― ΠΎΡΡΡΡΡΡΠ²ΠΎΠ²Π°Π»ΠΈ Ρ 35,8% Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΠΠ Π ΠΈ Ρ 21% Π»ΠΈΡ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΡ (p=0,006). ΠΠ±ΠΎΡΡΡΠ΅Π½ΠΈΠΉ ΠΠΠ Π ΠΈ Π½ΠΎΠ²ΡΡ
Π°ΡΡΠΎΠΈΠΌΠΌΡΠ½Π½ΡΡ
ΡΠ΅Π½ΠΎΠΌΠ΅Π½ΠΎΠ² Π½Π΅ Π·Π°ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π½ΠΎ Π½ΠΈ Π² ΠΎΠ΄Π½ΠΎΠΌ ΡΠ»ΡΡΠ°Π΅.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π‘ΠΎΠ³Π»Π°ΡΠ½ΠΎ ΠΏΡΠ΅Π΄Π²Π°ΡΠΈΡΠ΅Π»ΡΠ½ΡΠΌ Π΄Π°Π½Π½ΡΠΌ, Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΡ ΠΏΡΠΎΡΠΈΠ² COVID-19 Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΠΠ Π ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ΅ΡΡΡ Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΠΉ. ΠΠ΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΡ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠΈΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Ρ ΡΠ΅Π»ΡΡ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ, ΠΈΠΌΠΌΡΠ½ΠΎΠ³Π΅Π½Π½ΠΎΡΡΠΈ ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈΠΌΠΌΡΠ½ΠΈΠ·Π°ΡΠΈΠΈ ΠΏΡΠΎΡΠΈΠ² COVID-19 Ρ ΡΠ΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ²
QUANTUM-CHEMICAL QSAR-MODELING OF NA+/H+ EXCHANGER 1 INHIBITORS BASED ON THE CONSENSUS OF NEURAL NETWORKS
80-8
THE ENZYMATIC STATUS FEATURES IN BLOOD LYMPHOCYTES IN CHILDREN WITH DYSFUNCTIONAL DISORDERS OF BILIARY TRACT AND THEIR ASSOCIATION WITH GIARDIASIS
N the study of NAD(P)-dependent dehydrogenases activity in blood lymphocytes in children with dysfunctional disorders of the biliary tract (DDBT) and. DDBT in association with giardiasis detected significant changes in the intracellular metabolism. In children with DDBT in blood lymphocytes the levels of substrate flow decreased at the terminal reactions of glycolysis and. the tricarboxylic acid cycle, which determines the inhibition, respectively, anaerobic and aerobic cellular respiration. It's been established that in blood lymphocytes of children with DDBT, associated with giardiasis, the activity of enzymes determining the state of aerobic respiration is reduced, while maintaining the normal level of intensity of the terminal reactions of anaerobic glycolysis. Regardless of the presence or absence of giardiasis in children with DDBT the activity of pentose phosphate cycle is reduced which characterizes the inhibition of the reactions of macromolecular synthesis
Immunogenicity, safety and efficacy of 23-valent pneumococcal polysaccharide vaccine in patients with inflammatory joint diseases (preliminary data)
Intoduction. Currently, for the treatment of patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA), basic anti-inflammatory drugs and biological drugs are widely used to effectively control the activity of the disease. However, the use of these drugs is associated with an increased risk of developing comorbid infections, some of which can be prevented by vaccination. Objective. To evaluate the immunogenicity, safety, and clinical efficacy of the 23-valent pneumococcal polysaccharide vaccine (PPV-23) in patients with RA and SpA.Materials and methods. The study included 122 patients: 79 - with RA, 43-with SpA. Most patients had a history of two or more cases of lower respiratory tract infections, 2 patients reported a monthly exacerbation of chronic sinusitis, one patient reported the development of otitis media every 2-3 months. At the time of inclusion in the study, most patients received immunosuppressive therapy. PPV-23 was administered in an amount of 1 dose (0.5 ml) subcutaneously against the background of anti-rheumatic therapy. The level of antibodies to pneumococcal capsular polysaccharide was determined using the EIA PCP IgG kit (TestLine Clin-ical Diagnostics s.r.o., Czech Republic) before vaccination, 1, 3 and 12 months after vaccination. In addition, the tolerance of PPV-23, the frequency of pneumonia, and the effect on the activity of RA and SpA were evaluated (according to the dynamics of DAS28 and BASDAI).Results. At 1, 3, and 12 months after vaccination, the concentration of antibodies to pneumococcal capsular polysaccharide was significantly higher than the baseline values, which indicates sufficient immunogenicity of PPV-23. There was no negative effect of vaccination on the activity of the underlying disease and the occurrence of new autoimmune disorders. In the majority of patients (67% - RA, 81.4% - SpA), the tolerance of the vaccine was good. During the follow-up period, none of the patients developed pneumonia. Patients suffering from frequent sinusitis and otitis media reported the absence of these infections after vaccination.Conclusion. Preliminary results of the study indicate sufficient immunogenicity, safety, and clinical efficacy of PPV-23 in patients with RA and SpA
ΠΠ°ΠΊΡΠΈΠ½Π°ΡΠΈΡ ΠΏΡΠΎΡΠΈΠ² ΠΆΠ΅Π»ΡΠΎΠΉ Π»ΠΈΡ ΠΎΡΠ°Π΄ΠΊΠΈ ΠΏΡΠΈ ΡΠ΅Π²ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΡ
Yellow fever (YF) is an obligate, transmissible, feral herd infectious disease characterized by multiple organ dysfunction and high mortality rates. The intensification of international relations and tourist flows, including those to the YF endemic areas in recent years has substantially increased the value of vaccination against this infection in patients on immunosuppressive therapy for immunological disorders, including rheumatic diseases (RDs). In this connection, the recently published guidelines by the experts of the Brazilian Society of Rheumatology on the efficiency and safety of immunization against YL in patients with chronic immune-mediated inflammatory diseases (including RDs) are of great interest. The main provisions of these guidelines are presented in this paper.ΠΠ΅Π»ΡΠ°Ρ Π»ΠΈΡ
ΠΎΡΠ°Π΄ΠΊΠ° (ΠΠ) β ΠΎΠ±Π»ΠΈΠ³Π°ΡΠ½ΠΎΠ΅ ΡΡΠ°Π½ΡΠΌΠΈΡΡΠΈΠ²Π½ΠΎΠ΅ ΠΏΡΠΈΡΠΎΠ΄Π½ΠΎ-ΠΎΡΠ°Π³ΠΎΠ²ΠΎΠ΅ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΎΠ½Π½ΠΎΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅, Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΡΡΠ΅Π΅ΡΡ ΠΏΠΎΠ»ΠΈΠΎΡΠ³Π°Π½Π½ΡΠΌ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΠΈ Π²ΡΡΠΎΠΊΠΎΠΉ Π»Π΅ΡΠ°Π»ΡΠ½ΠΎΡΡΡΡ. ΠΠ½ΡΠ΅Π½ΡΠΈΡΠΈΠΊΠ°ΡΠΈΡ ΠΌΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½ΡΡ
ΡΠ²ΡΠ·Π΅ΠΉ ΠΈ ΡΡΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΠΎΡΠΎΠΊΠΎΠ², Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ Π² ΡΠ½Π΄Π΅ΠΌΠΈΡΠ½ΡΠ΅ ΠΏΠΎ ΠΠ ΡΠ΅Π³ΠΈΠΎΠ½Ρ, Π² ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΠ΅ Π³ΠΎΠ΄Ρ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ ΠΏΠΎΠ²ΡΡΠΈΠ»Π° Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ Π²Π°ΠΊΡΠΈΠ½ΠΎΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ Π΄Π°Π½Π½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π½Π°ΡΡΡΠ΅Π½ΠΈΡΠΌΠΈ, Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ Ρ ΡΠ΅Π²ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ (Π Π), ΠΏΠΎΠ»ΡΡΠ°ΡΡΠΈΡ
ΠΈΠΌΠΌΡΠ½ΠΎΡΡΠΏΡΠ΅ΡΡΠΈΠ²Π½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ. Π ΡΠ²ΡΠ·ΠΈ Ρ ΡΡΠΈΠΌ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΡΡ Π±ΠΎΠ»ΡΡΠΎΠΉ ΠΈΠ½ΡΠ΅ΡΠ΅Ρ Π½Π΅Π΄Π°Π²Π½ΠΎ ΠΎΠΏΡΠ±Π»ΠΈΠΊΠΎΠ²Π°Π½Π½ΡΠ΅ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΈ ΡΠΊΡΠΏΠ΅ΡΡΠΎΠ² ΠΡΠ°Π·ΠΈΠ»ΡΡΠΊΠΎΠ³ΠΎ ΠΎΠ±ΡΠ΅ΡΡΠ²Π° ΡΠ΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΎΠ², ΠΏΠΎΡΠ²ΡΡΠ΅Π½Π½ΡΠ΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΠΈΠΌΠΌΡΠ½ΠΈΠ·Π°ΡΠΈΠΈ ΠΏΡΠΎΡΠΈΠ² ΠΠ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΠΎΠΏΠΎΡΡΠ΅Π΄ΠΎΠ²Π°Π½Π½ΡΠΌΠΈ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ (Π²ΠΊΠ»ΡΡΠ°Ρ Π Π). ΠΡΠ½ΠΎΠ²Π½ΡΠ΅ ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΡ ΡΡΠΈΡ
ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΉ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ Π² Π½Π°ΡΡΠΎΡΡΠ΅ΠΉ ΠΏΡΠ±Π»ΠΈΠΊΠ°ΡΠΈΠΈ
ΠΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΡΠ΅ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΠΏΡΠΈ ΡΠΏΠΎΠ½Π΄ΠΈΠ»ΠΎΠ°ΡΡΡΠΈΡΠ°Ρ : ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠΉ Π²Π·Π³Π»ΡΠ΄ Π½Π° ΠΏΡΠΎΠ±Π»Π΅ΠΌΡ
The review considers the problem of comorbid infections (CIs) in ankylosing spondylitis and psoriatic arthritis (PsA) as the main nosological entities of spondyloarthritis (SpA). It analyzes the frequency of CIs during therapy with biological agents and targeted synthetic disease-modifying anti-rheumatic drugs. It is concluded that the problem of CI in SpA deserves the closest attention. The review also shows the importance of preventive measures for CI in the treatment of SpA. It is in particular noted that in accordance with the updated guidelines of the European League Against Rheumatism and other rheumatology research associations, all patients with immunemediated inflammatory rheumatic diseases (including SpA) on immunosuppressive therapy are recommended to get influenza and pneumococcal vaccines due to the high risk of death from respiratory tract infections. Moreover, vaccination is indicated even for patients with an expected suboptimal response. The review gives the main points of the recommendations of the Medical Board of the National Psoriasis (Ps) Foundation on the use of recombinant Herpes zoster vaccine in patients with Ps/PsA. There is a need for further investigations of the frequency and pattern of CIs and the impact of new therapy options on the prevalence of CIs in patients with SpA. Determination of the effectiveness and safety of vaccination in this patient population should become an important area for future investigations.Π ΠΎΠ±Π·ΠΎΡΠ΅ ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°Π΅ΡΡΡ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ° ΠΊΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΡΡ
ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ (ΠΠ) ΠΏΡΠΈ Π°Π½ΠΊΠΈΠ»ΠΎΠ·ΠΈΡΡΡΡΠ΅ΠΌ ΡΠΏΠΎΠ½Π΄ΠΈΠ»ΠΈΡΠ΅ ΠΈ ΠΏΡΠΎΡΠΈΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΌ Π°ΡΡΡΠΈΡΠ΅ (ΠΡΠ) ΠΊΠ°ΠΊ ΠΎΡΠ½ΠΎΠ²Π½ΡΡ
Π½ΠΎΠ·ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΎΡΠΌΠ°Ρ
ΡΠΏΠΎΠ½Π΄ΠΈΠ»ΠΎΠ°ΡΡΡΠΈΡΠΎΠ² (Π‘ΠΏΠ). ΠΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π° ΡΠ°ΡΡΠΎΡΠ° ΠΠ Π½Π° ΡΠΎΠ½Π΅ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π³Π΅Π½Π½ΠΎ-ΠΈΠ½ΠΆΠ΅Π½Π΅ΡΠ½ΡΠΌΠΈ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°ΠΌΠΈ ΠΈ ΡΠ°ΡΠ³Π΅ΡΠ½ΡΠΌΠΈ ΡΠΈΠ½ΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π±Π°Π·ΠΈΡΠ½ΡΠΌΠΈ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠΌΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°ΠΌΠΈ. Π‘Π΄Π΅Π»Π°Π½ΠΎ Π·Π°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅, ΡΡΠΎ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ° ΠΠ ΠΏΡΠΈ Π‘ΠΏΠ Π·Π°ΡΠ»ΡΠΆΠΈΠ²Π°Π΅Ρ ΡΠ°ΠΌΠΎΠ³ΠΎ ΠΏΡΠΈΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π²Π½ΠΈΠΌΠ°Π½ΠΈΡ. ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΠΏΡΠ΅Π²Π΅Π½ΡΠΈΠ²Π½ΡΡ
ΠΌΠ΅ΡΠΎΠΏΡΠΈΡΡΠΈΠΉ Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ ΠΠ ΠΏΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π‘ΠΏΠ. Π ΡΠ°ΡΡΠ½ΠΎΡΡΠΈ, ΠΎΡΠΌΠ΅ΡΠ΅Π½ΠΎ, ΡΡΠΎ Π² ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΠΈΠΈ Ρ ΠΎΠ±Π½ΠΎΠ²Π»Π΅Π½Π½ΡΠΌΠΈ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΡΠΌΠΈ ΠULAR ΠΈ Π΄ΡΡΠ³ΠΈΡ
Π½Π°ΡΡΠ½ΡΡ
ΡΠ΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π°ΡΡΠΎΡΠΈΠ°ΡΠΈΠΉ Π²ΡΠ΅ΠΌ Π±ΠΎΠ»ΡΠ½ΡΠΌ Ρ ΠΈΠΌΠΌΡΠ½ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠΌΠΈ ΡΠ΅Π²ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ (Π²ΠΊΠ»ΡΡΠ°Ρ Π‘ΠΏΠ), ΠΏΠΎΠ»ΡΡΠ°ΡΡΠΈΠΌ ΠΈΠΌΠΌΡΠ½ΠΎΡΡΠΏΡΠ΅ΡΡΠΈΠ²Π½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ, ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄ΡΠ΅ΡΡΡ ΠΈΠΌΠΌΡΠ½ΠΈΠ·Π°ΡΠΈΡ Π³ΡΠΈΠΏΠΏΠΎΠ·Π½ΠΎΠΉ ΠΈ ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ Π²Π°ΠΊΡΠΈΠ½Π°ΠΌΠΈ ΠΈΠ·-Π·Π° Π²ΡΡΠΎΠΊΠΎΠ³ΠΎ ΡΠΈΡΠΊΠ° Π»Π΅ΡΠ°Π»ΡΠ½ΡΡ
ΠΈΡΡ
ΠΎΠ΄ΠΎΠ², ΠΎΠ±ΡΡΠ»ΠΎΠ²Π»Π΅Π½Π½ΡΡ
ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΎΠ½Π½ΠΎΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠ΅ΠΉ Π΄ΡΡ
Π°ΡΠ΅Π»ΡΠ½ΡΡ
ΠΏΡΡΠ΅ΠΉ. ΠΡΠΈ ΡΡΠΎΠΌ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΡ ΠΏΠΎΠΊΠ°Π·Π°Π½Π° Π΄Π°ΠΆΠ΅ Π±ΠΎΠ»ΡΠ½ΡΠΌ Ρ ΠΎΠΆΠΈΠ΄Π°Π΅ΠΌΡΠΌ ΡΡΠ±ΠΎΠΏΡΠΈΠΌΠ°Π»ΡΠ½ΡΠΌ ΠΎΡΠ²Π΅ΡΠΎΠΌ. ΠΡΠΈΠ²Π΅Π΄Π΅Π½Ρ ΠΎΡΠ½ΠΎΠ²Π½ΡΠ΅ ΠΏΡΠ½ΠΊΡΡ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΉ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠ³ΠΎ ΡΠΎΠ²Π΅ΡΠ° ΠΠ°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠΎΠ½Π΄Π° Π±ΠΎΡΡΠ±Ρ Ρ ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ (ΠΡ) ΠΏΠΎ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΠΎΠΉ Π²Π°ΠΊΡΠΈΠ½Ρ ΠΏΡΠΎΡΠΈΠ² ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Herpes zoster (RHZV) Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΡ/ΠΡΠ. ΠΠ΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΡ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠΈΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ°ΡΡΠΎΡΡ ΠΈ ΡΡΡΡΠΊΡΡΡΡ ΠΠ, Π° ΡΠ°ΠΊΠΆΠ΅ Π²Π»ΠΈΡΠ½ΠΈΡ Π½ΠΎΠ²ΡΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π½Π° ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΡΡΡ ΠΠ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Π‘ΠΏΠ. ΠΠ°ΠΆΠ½ΡΠΌ Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΠ΅ΠΌ Π±ΡΠ΄ΡΡΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Π΄ΠΎΠ»ΠΆΠ½ΠΎ ΡΡΠ°ΡΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ Ρ Π΄Π°Π½Π½ΠΎΠ³ΠΎ ΠΊΠΎΠ½ΡΠΈΠ½Π³Π΅Π½ΡΠ° Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΡΠ΅ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ ΡΠΏΠΎΠ½Π΄ΠΈΠ»ΠΎΠ°ΡΡΡΠΈΡΠ°ΠΌΠΈ: ΡΠ°ΡΡΠΎΡΠ°, ΡΡΡΡΠΊΡΡΡΠ°, ΡΠ°ΠΊΡΠΎΡΡ ΡΠΈΡΠΊΠ°
Objective: To investigate the frequency, structure, and risk factors of comorbid infections (CI) in patients with spondyloarthritis (SpA).Material and methods. The study included 332 patients with SpA. Patients were interviewed by the investigating physician, and additional information was obtained from medical records.Results and discussion. Respiratory tract (RT) and ear, nose, and throat (ENT) infections ranked first in the structure of CI. Exacerbation of SpA after CI was found in 42% of patients, and more severe CI against the background of SpA was found in 83 patients. 63 cases of severe CI (SCI) were documented, 63.5% of which were infections of the RT and ENT organs. Predictors for the development of lower RT (LRT) and ENT organ infections were the use of biologic disease-modifying antirheumatic drugs (bDMARDs) in general (odds ratio, OR 2.018; 95% confidence interval, CI 1.221-3.335; p=0.006 and OR 1.761; 95% CI 1.1-2.819, respectively; p=0.018) and tumor necrosis factor-Ξ± (TNF-Ξ±) inhibitors in particular (OR 2.376; 95% CI 1.417-3.983; p=0.001 and OR 1.833; 95% CI 1.123-2.994; p=0.015), and disease duration of more than 5 years (OR 1.774; 95% CI 1.034β3.042; p=0.037 and OR 2.22; 95% CI 1.378-3.576; p=0.001). The risk of developing LRT infection was higher in the presence of chronic lung disease (OR 3.673; 95% CI 1.602-8.425; p=0.002) and Charlesson Comorbidity Index β₯1 (OR 2.381; 95% CI 1.439-3.94; p=0.001), risk of developing ENT organ infections - with the use of >1 bDMARD (OR 2.4; 95% CI 1.199-4.804; p=0.013) and duration of methotrexate therapy over 5 years (OR 2.478; 95% CI 1.053-5.831; p=0.038). Risk factors for the development of SCI were the use of bDMARDs in general (OR 1.941; 95% CI 1.063-3.545; p=0.031) and TNFΞ± in particular (OR 2.246; 95%, CI 1.218-4.139; p=0.01).Conclusion. The problem of CI in SpA is of great importance. The vast majority of patients with SpA should be vaccinated against pneumococcal infection and influenza.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΈΠ·ΡΡΠΈΡΡ ΡΠ°ΡΡΠΎΡΡ, ΡΡΡΡΠΊΡΡΡΡ ΠΈ ΡΠ°ΠΊΡΠΎΡΡ ΡΠΈΡΠΊΠ° ΠΊΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΡΡ
ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ (ΠΠ) Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠΏΠΎΠ½Π΄ΠΈΠ»ΠΎΠ°ΡΡΡΠΈΡΠ°ΠΌΠΈ (Π‘ΠΏΠ).ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΎ 332 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° ΡΠΎ Π‘ΠΏΠ. ΠΠΎΠ»ΡΠ½ΡΠ΅ Π±ΡΠ»ΠΈ ΠΎΠΏΡΠΎΡΠ΅Π½Ρ Π²ΡΠ°ΡΠΎΠΌ-ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»Π΅ΠΌ, Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΡΡ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡ ΠΏΠΎΠ»ΡΡΠ°Π»ΠΈ ΠΈΠ· ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΉ Π΄ΠΎΠΊΡΠΌΠ΅Π½ΡΠ°ΡΠΈΠΈ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈ ΠΎΠ±ΡΡΠΆΠ΄Π΅Π½ΠΈΠ΅. ΠΠ΅Π΄ΡΡΠ΅Π΅ ΠΌΠ΅ΡΡΠΎ Π² ΡΡΡΡΠΊΡΡΡΠ΅ ΠΠ Π·Π°Π½ΠΈΠΌΠ°Π»ΠΈ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Π΄ΡΡ
Π°ΡΠ΅Π»ΡΠ½ΡΡ
ΠΏΡΡΠ΅ΠΉ (ΠΠ) ΠΈ ΠΠΠ -ΠΎΡΠ³Π°Π½ΠΎΠ². Π£ 42% Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΎΡΠΌΠ΅ΡΠ΅Π½ΠΎ ΠΎΠ±ΠΎΡΡΡΠ΅Π½ΠΈΠ΅ Π‘ΠΏΠ ΠΏΠΎΡΠ»Π΅ ΠΏΠ΅ΡΠ΅Π½Π΅ΡΠ΅Π½Π½ΠΎΠΉ ΠΠ, Ρ 83 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² β Π±ΠΎΠ»Π΅Π΅ ΡΡΠΆΠ΅Π»ΠΎΠ΅ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΠ Π½Π° ΡΠΎΠ½Π΅ Π‘ΠΏΠ. ΠΠΎΠΊΡΠΌΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½ΠΎ 63 ΡΠ»ΡΡΠ°Ρ ΡΠ΅ΡΡΠ΅Π·Π½ΡΡ
ΠΠ(Π‘ΠΠ), 63,5% ΠΈΠ· Π½ΠΈΡ
β ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΠΠ ΠΈ ΠΠΠ -ΠΎΡΠ³Π°Π½ΠΎΠ². ΠΡΠ΅Π΄ΠΈΠΊΡΠΎΡΠ°ΠΌΠΈ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ Π½ΠΈΠΆΠ½ΠΈΡ
ΠΠ(ΠΠΠ) ΠΈ ΠΠΠ -ΠΎΡΠ³Π°Π½ΠΎΠ² ΡΠ²Π»ΡΠ»ΠΈΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ Π³Π΅Π½Π½ΠΎ-ΠΈΠ½ΠΆΠ΅Π½Π΅ΡΠ½ΡΡ
Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² (ΠΠΠΠ) Π² ΡΠ΅Π»ΠΎΠΌ (ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅ ΡΠ°Π½ΡΠΎΠ², ΠΠ¨ 2,018; 95% ΠΠΎΠ²Π΅ΡΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΠΈΠ½ΡΠ΅ΡΠ²Π°Π», ΠΠ 1,221β3,335; Ρ=0,006 ΠΈ ΠΠ¨ 1,761; 95% ΠΠ 1,1β2,819 ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ; Ρ=0,018) ΠΈ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠΎΠ² ΡΠ°ΠΊΡΠΎΡΠ° Π½Π΅ΠΊΡΠΎΠ·Π° ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ Ξ± (ΠΈΠ€ΠΠΞ±) Π² ΡΠ°ΡΡΠ½ΠΎΡΡΠΈ (ΠΠ¨ 2,376; 95% ΠΠ 1,417β3,983;Ρ=0,001 ΠΈ ΠΠ¨ 1,833; 95% ΠΠ 1,123β2,994; Ρ=0,015), Π° ΡΠ°ΠΊΠΆΠ΅ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Π±ΠΎΠ»Π΅Π΅ 5 Π»Π΅Ρ (ΠΠ¨ 1,774; 95% ΠΠ 1,034β3,042; Ρ=0,037 ΠΈ ΠΠ¨ 2,22; 95% ΠΠ 1,378β3,576; Ρ=0,001). Π ΠΈΡΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ ΠΠΠ Π±ΡΠ» Π²ΡΡΠ΅ ΠΏΡΠΈ Π½Π°Π»ΠΈΡΠΈΠΈ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Π»Π΅Π³ΠΊΠΈΡ
(ΠΠ¨ 3,673; 95% ΠΠ 1,602β8,425; Ρ=0,002) ΠΈ ΠΈΠ½Π΄Π΅ΠΊΡΠ° ΠΊΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΠΎΡΡΠΈ Π§Π°ΡΠ»ΡΡΠΎΠ½Π° β₯1 (ΠΠ¨ 2,381; 95% ΠΠ 1,439β3,94; Ρ=0,001), ΡΠΈΡΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ ΠΠΠ -ΠΎΡΠ³Π°Π½ΠΎΠ² β ΠΏΡΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠΈ >1 ΠΠΠΠ (ΠΠ¨ 2,4; 95% ΠΠ 1,199β4,804; Ρ=0,013) ΠΈ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΌΠ΅ΡΠΎΡΡΠ΅ΠΊΡΠ°ΡΠΎΠΌ Π±ΠΎΠ»Π΅Π΅ 5 Π»Π΅Ρ (ΠΠ¨ 2,478; 95% ΠΠ 1,053β5,831; Ρ=0,038). Π€Π°ΠΊΡΠΎΡΠ°ΠΌΠΈ ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ Π‘ΠΠ Π±ΡΠ»ΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΠΠΠ Π² ΡΠ΅Π»ΠΎΠΌ (ΠΠ¨ 1,941; 95% ΠΠ 1,063-3,545;Ρ=0,031) ΠΈ ΠΈΠ€ΠΠΞ± Π² ΡΠ°ΡΡΠ½ΠΎΡΡΠΈ (ΠΠ¨ 2,246; 95% ΠΠ 1,218-4,139;Ρ=0,01).ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΡΠΎΠ±Π»Π΅ΠΌΠ° ΠΠ ΠΏΡΠΈ Π‘ΠΏΠ ΡΠ²Π»ΡΠ΅ΡΡΡ Π²Π΅ΡΡΠΌΠ° Π°ΠΊΡΡΠ°Π»ΡΠ½ΠΎΠΉ. Π£ ΠΏΠΎΠ΄Π°Π²Π»ΡΡΡΠ΅Π³ΠΎ ΡΠΈΡΠ»Π° Π±ΠΎΠ»ΡΠ½ΡΡ
Π‘ΠΏΠ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΡΡ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΡ ΠΏΡΠΎΡΠΈΠ² ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΠΈ Π³ΡΠΈΠΏΠΏΠ°
ΠΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ Π²Π°ΠΊΡΠΈΠ½Ρ ΠΠ°ΠΌ-ΠΠΠΠΠ-ΠΠ°ΠΊ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΈΠΌΠΌΡΠ½ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠΌΠΈ ΡΠ΅Π²ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ: ΠΏΡΠ΅Π΄Π²Π°ΡΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΠΏΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ
Objective: to study the efficacy and safety of the Gam-COVID-Vac vaccine in patients with immunoinflammatory rheumatic diseases (IRD) in a prospective study.Material and methods. The study included 42 patients with IRD and 57 individuals without IRD (control group) who received at least one component of Gam-COVID-Vac. Immunization with the first component of the vaccine was carried out from March 25th to August 1st, 2022, the second β 3 weeks after the first dose. On days 1, 3 and 7 after administration of the first and second components, the study participants provided information on adverse events (AEs) by telephone. All subjects were examined by a rheumatologist 1, 3 and 6 months after complete immunization. The observation period after immunization with the second dose was 6 months.Results and discussion. 42 patients received the first component of the vaccine, and 39 patients received two components. In the control group, 57 subjects were immunized with two components of the vaccine. 30β180 days after vaccination with two components of Gam-COVID-Vac, 3 (7.7%) patients were diagnosed with SARS-CoV-2 infection, which was confirmed by polymerase chain reaction. In all cases, a mild course of COVID-19 without signs of pneumonia was observed. There were no cases of COVID-19 in the control group. After immunization with the first component, a combination of at least one local and one systemic AE (SAE) was documented in 28.6% of patients with IRD and 33.3% of individuals in the control group (p>0.05). No AEs were recorded in 42.9% and 36.8% of cases respectively (p>0.05). After vaccination with the second component, a combination of β₯1 local AE and SAE was recorded in 15.4 % of patients with IRD and 22.8% of individuals in the control group (p>0.05). No AEs occurred in 71.8% and 56.1% of cases respectively (p>0.05). In 10.3% of patients with IRD and 12.3 % of those without IRD (p>0.05), a combination of local and systemic AEs was recorded after the introduction of both first and second components. No AEs were observed in 35.9% and 28.1% of cases, respectively (p>0.05). The overall rate of IRD exacerbations was 4.8%.Conclusion. Based on the available data, vaccination against COVID-19 appears to be effective and quite safe in patients with IRD.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΈΠ·ΡΡΠΈΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ Π²Π°ΠΊΡΠΈΠ½Ρ ΠΠ°ΠΌ-ΠΠΠΠΠ-ΠΠ°ΠΊ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΈΠΌΠΌΡΠ½ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠΌΠΈ ΡΠ΅Π²ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ (ΠΠΠ Π) Π² ΠΏΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΎ 42 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Ρ ΠΠΠ Π ΠΈ 57 Π»ΠΈΡ Π±Π΅Π· ΠΠΠ Π (ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½Π°Ρ Π³ΡΡΠΏΠΏΠ°), ΠΏΠΎΠ»ΡΡΠΈΠ²ΡΠΈΡ
ΠΊΠ°ΠΊ ΠΌΠΈΠ½ΠΈΠΌΡΠΌ ΠΎΠ΄ΠΈΠ½ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½Ρ ΠΠ°ΠΌ-ΠΠΠΠΠ-ΠΠ°ΠΊ. ΠΠΌΠΌΡΠ½ΠΈΠ·Π°ΡΠΈΡ ΠΏΠ΅ΡΠ²ΡΠΌ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠΎΠΌ Π²Π°ΠΊΡΠΈΠ½Ρ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»Π°ΡΡ Ρ 25 ΠΌΠ°ΡΡΠ° ΠΏΠΎ 1 Π°Π²Π³ΡΡΡΠ° 2022 Π³., Π²ΡΠΎΡΡΠΌ β ΡΠ΅ΡΠ΅Π· 3 Π½Π΅Π΄ ΠΏΠΎΡΠ»Π΅ Π²Π²Π΅Π΄Π΅Π½ΠΈΡ ΠΏΠ΅ΡΠ²ΠΎΠΉ Π΄ΠΎΠ·Ρ. Π 1-ΠΉ, Π½Π° 3-ΠΉ ΠΈ 7-ΠΉ Π΄Π΅Π½Ρ ΠΏΠΎΡΠ»Π΅ Π²Π²Π΅Π΄Π΅Π½ΠΈΡ ΠΏΠ΅ΡΠ²ΠΎΠ³ΠΎ ΠΈ Π²ΡΠΎΡΠΎΠ³ΠΎ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠΎΠ² ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡ ΠΎ Π½Π΅ΠΆΠ΅Π»Π°ΡΠ΅Π»ΡΠ½ΡΡ
ΡΠ²Π»Π΅Π½ΠΈΡΡ
(ΠΠ―) ΡΡΠ°ΡΡΠ½ΠΈΠΊΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠΎΠΎΠ±ΡΠ°Π»ΠΈ ΠΏΠΎ ΡΠ΅Π»Π΅ΡΠΎΠ½Ρ. Π§Π΅ΡΠ΅Π· 1, 3 ΠΈ 6 ΠΌΠ΅Ρ ΠΏΠΎΡΠ»Π΅ ΠΏΠΎΠ»Π½ΠΎΠΉ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ Π²ΡΠ΅ ΠΎΠ½ΠΈ Π±ΡΠ»ΠΈ ΠΎΡΠΌΠΎΡΡΠ΅Π½Ρ ΡΠ΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΎΠΌ. ΠΠ΅ΡΠΈΠΎΠ΄ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ ΠΏΠΎΡΠ»Π΅ ΠΈΠΌΠΌΡΠ½ΠΈΠ·Π°ΡΠΈΠΈ Π²ΡΠΎΡΠΎΠΉ Π΄ΠΎΠ·ΠΎΠΉ ΡΠΎΡΡΠ°Π²ΠΈΠ» 6 ΠΌΠ΅Ρ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈ ΠΎΠ±ΡΡΠΆΠ΄Π΅Π½ΠΈΠ΅. ΠΠ΅ΡΠ²ΡΠΉ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½Ρ Π²Π°ΠΊΡΠΈΠ½Ρ ΠΏΠΎΠ»ΡΡΠΈΠ»ΠΈ 42 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°, Π΄Π²Π° ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠ° β 39. Π ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΠ΅ 57 ΠΈΡΠΏΡΡΡΠ΅ΠΌΡΡ
ΠΈΠΌΠΌΡΠ½ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Ρ Π΄Π²ΡΠΌΡ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠ°ΠΌΠΈ Π²Π°ΠΊΡΠΈΠ½Ρ. Π§Π΅ΡΠ΅Π· 30β180 Π΄Π½Π΅ΠΉ ΠΏΠΎΡΠ»Π΅ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ Π΄Π²ΡΠΌΡ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠ°ΠΌΠΈ ΠΠ°ΠΌ-ΠΠΠΠΠ-ΠΠ°ΠΊ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΡ SARS-CoV-2, ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π΅Π½Π½Π°Ρ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ, Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠΎΠ²Π°Π½Π° Ρ 3 (7,7%) Π±ΠΎΠ»ΡΠ½ΡΡ
. ΠΡΠΈ ΡΡΠΎΠΌ Π²ΠΎ Π²ΡΠ΅Ρ
ΡΠ»ΡΡΠ°ΡΡ
ΠΎΡΠΌΠ΅ΡΠ΅Π½ΠΎ Π»Π΅Π³ΠΊΠΎΠ΅ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ COVID-19 Π±Π΅Π· ΠΏΡΠΈΠ·Π½Π°ΠΊΠΎΠ² ΠΏΠ½Π΅Π²ΠΌΠΎΠ½ΠΈΠΈ. Π ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΠ΅ ΡΠ»ΡΡΠ°Π΅Π² COVID-19 Π½Π΅ Π±ΡΠ»ΠΎ. ΠΠΎΡΠ»Π΅ ΠΈΠΌΠΌΡΠ½ΠΈΠ·Π°ΡΠΈΠΈ ΠΏΠ΅ΡΠ²ΡΠΌ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠΎΠΌ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ ΠΊΠ°ΠΊ ΠΌΠΈΠ½ΠΈΠΌΡΠΌ 1 ΠΌΠ΅ΡΡΠ½ΠΎΠ³ΠΎ ΠΈ 1 ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠ³ΠΎ ΠΠ― (Π‘ΠΠ―) Π΄ΠΎΠΊΡΠΌΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½ΠΎ Ρ 28,6% ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΠΠ Π ΠΈ 33,3% Π»ΠΈΡ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΡ (p>0,05). ΠΠ― Π½Π΅ Π·Π°ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π½Ρ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ Π² 42,9% ΠΈ 36,8% ΡΠ»ΡΡΠ°Π΅Π² (p>0,05). ΠΠΎΡΠ»Π΅ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ Π²ΡΠΎΡΡΠΌ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠΎΠΌ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ 1 ΠΌΠ΅ΡΡΠ½ΠΎΠ³ΠΎ ΠΠ― ΠΈ Π‘ΠΠ― Π·Π°ΡΠΈΠΊΡΠΈΡΠΎΠ²Π°Π½ΠΎ Ρ 15,4% Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΠΠ Π ΠΈ 22,8% Π»ΠΈΡ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΡ (p>0,05). ΠΠ― ΠΎΡΡΡΡΡΡΠ²ΠΎΠ²Π°Π»ΠΈ Π² 71,8% ΠΈ 56,1% ΡΠ»ΡΡΠ°Π΅Π² ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ (p>0,05). Π£ 10,3% ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΠΠ Π ΠΈ 12,3% Π»ΠΈΡ Π±Π΅Π· ΠΠΠ Π (p>0,05) ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ ΠΌΠ΅ΡΡΠ½ΡΡ
ΠΈ ΡΠΈΡΡΠ΅ΠΌΠ½ΡΡ
ΠΠ― Π·Π°ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π½ΠΎ ΠΏΠΎΡΠ»Π΅ Π²Π²Π΅Π΄Π΅Π½ΠΈΡ ΠΊΠ°ΠΊ ΠΏΠ΅ΡΠ²ΠΎΠ³ΠΎ, ΡΠ°ΠΊ ΠΈ Π²ΡΠΎΡΠΎΠ³ΠΎ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠ°. ΠΠ΅ ΠΎΡΠΌΠ΅ΡΠ΅Π½ΠΎ ΠΠ― Π² 35,9% ΠΈ 28,1% ΡΠ»ΡΡΠ°Π΅Π² ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ (p>0,05). ΠΠ±ΡΠ°Ρ ΡΠ°ΡΡΠΎΡΠ° ΠΎΠ±ΠΎΡΡΡΠ΅Π½ΠΈΠΉ ΠΠΠ Π ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 4,8%.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π‘ΠΎΠ³Π»Π°ΡΠ½ΠΎ ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΠΌ Π΄Π°Π½Π½ΡΠΌ, Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΡ ΠΏΡΠΎΡΠΈΠ² COVID-19 Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΠΠ Π ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ΅ΡΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ ΠΈ Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΠΉ